These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 24495591)

  • 41. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.
    Berghmans T; Lafitte JJ; Thiriaux J; VanHoutte P; Lecomte J; Efremidis A; Koumakis G; Giner V; Richez M; Corhay JL; Wackenier P; Lothaire P; Mommen P; Ninane V; Sculier JP;
    Lung Cancer; 2004 Sep; 45(3):339-48. PubMed ID: 15301874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
    Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy.
    Wei X; Liu HH; Tucker SL; Liao Z; Hu C; Mohan R; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):100-7. PubMed ID: 16839700
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients.
    Jeremić B; Miličić B; Milisavljevic S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1157-63. PubMed ID: 21640518
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer.
    Zhao L; West BT; Hayman JA; Lyons S; Cease K; Kong FM
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):103-10. PubMed ID: 17363189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
    Seung SK; Ross HJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):802-9. PubMed ID: 18762390
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Radiation therapy for lung cancer].
    Shibuya K; Hiraoka M
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):544-9. PubMed ID: 17431339
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
    Koshy M; Malik R; Spiotto M; Mahmood U; Rusthoven CG; Sher DJ
    Lung Cancer; 2017 Jun; 108():222-227. PubMed ID: 28625640
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
    Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
    Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K; Blacksburg S; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study.
    Kong FM; Ten Haken RK; Schipper MJ; Sullivan MA; Chen M; Lopez C; Kalemkerian GP; Hayman JA
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):324-33. PubMed ID: 16168827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
    Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
    Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume.
    Feng W; Zhang Q; Fu XL; Cai XW; Zhu ZF; Yang HJ; Xiang JQ; Zhang YW; Chen HQ
    BMC Cancer; 2015 May; 15():348. PubMed ID: 25934006
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer.
    Widder J; Postmus D; Ubbels JF; Wiegman EM; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e291-7. PubMed ID: 21640503
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer.
    Liu HH; Wang X; Dong L; Wu Q; Liao Z; Stevens CW; Guerrero TM; Komaki R; Cox JD; Mohan R
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1268-79. PubMed ID: 15001272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities.
    Shirvani SM; Jiang J; Gomez DR; Chang JY; Buchholz TA; Smith BD
    Lung Cancer; 2013 Nov; 82(2):252-9. PubMed ID: 24018022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcomes following surgical treatment compared to radiation for stage I NSCLC: a SEER database analysis.
    Monirul Islam KM; Shostrom V; Kessinger A; Ganti AK
    Lung Cancer; 2013 Oct; 82(1):90-4. PubMed ID: 23910907
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy.
    Liao ZX; Komaki RR; Thames HD; Liu HH; Tucker SL; Mohan R; Martel MK; Wei X; Yang K; Kim ES; Blumenschein G; Hong WK; Cox JD
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):775-81. PubMed ID: 19515503
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
    Tang C; Lee MS; Gomez D; Levy LB; Zhuang Y; Lu C; Liao Z; Komaki R
    Am J Clin Oncol; 2017 Dec; 40(6):625-630. PubMed ID: 26165417
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical application of a novel hybrid intensity-modulated radiotherapy technique for stage III lung cancer and dosimetric comparison with four other techniques.
    Verbakel WF; van Reij E; Ladenius-Lischer I; Cuijpers JP; Slotman BJ; Senan S
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e297-303. PubMed ID: 22579380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.